Wabei.com On May 4, Chenxin Pharmaceutical (603367) released the report for the first quarter of 2022. During the reporting period, the company achieved operating income of 869,770,720.65 yuan, a year-on-year decrease of 0.45%; net profit attributable to shareholders of the listed company was 96,747,943.51 yuan, a year-on-year decrease of 0.45%. down 10.99%.
During the reporting period, the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was RMB 90,935,465.75, and the total assets as at the end of the reporting period were RMB 6,311,113,641.66.
During the reporting period, the company’s management expenses increased by 52.33% year-on-year; employee compensation and storage costs increased during the reporting period. Investment income fell by 93.34% year-on-year, and the wealth management income received during the reporting period decreased.
According to the data of Wabei.com, Chenxin Pharmaceutical is mainly engaged in the research and development, production and sales of chemical preparations. The products cover large-capacity injections (including non-PVC soft bags, plastic bottles, stand-up bags, glass bottles), freeze-dried powder injections, small There are 202 varieties of 5 major dosage forms, including volume injections, tablets and capsules, with a total of 340 specifications.